glp-1 receptor agonists in pediatric and adolescent obesity Nutritional priorities to support therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Medicine Association, The Obesity Society GLP-1 Agonists For Obesity In

Lillys approval for Mounjaro in Obesity will result in a duopoly in the space, with clinical stage biopharma (mentioned below) likely 2 years from having a drug on the market

[37] conducted a randomized, double-blind, phase 2 trial where adults aged 1875 years with type 2 diabetes, HbA1c of 7.010.5%, and BMI of 2550 kg/m 2 were eligible for enrolment

Nauck MA, Kemmeries G, Holst JJ, Meier JJ

STATEMENT OF AUTHORSHIP Category 1: a

Initially, the NHS has made Mounjaro available to patients at greatest risk of ill health, or who are experiencing severe ill health due to living with obesity

All authors have read and agreed to the published version of the manuscript